Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
LaggingIntegra LifeSciences Holdings Corporation is a global medical technology company dedicated to restoring lives. We are advancing transformational care through impactful innovation and our portfolio of highly differentiated technologies is trusted by healthcare professionals to deliver transformative care. We manufacture and sell medical technologies and products in two reportable business segments: Codman Specialty Surgical (“CSS”) and Tissue Technologies (“TT”).
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
Business segments
Jun 2026 · $418.8MThe company’s own SEC segment disclosure.
- Neurosurgery$213.3M51%
- Wound Reconstruction Solutions$81.3M19%
- Surgical Instruments$54.8M13%
- ENT Solutions$41.2M10%
- Private Label$28.2M7%
Integra LifeSciences Holdings Corporation (IART) reported revenue of $392M in Q1 2026 (quarter ended Mar 31, 2026), up 2.4% from the same quarter a year earlier. That came with a gross margin of 55% and net loss of $4.6M. For the full year FY2025, revenue was $1.64B (+1.5% year on year) and net income −$516M. Its largest product in Jun 2026 was Neurosurgery at $213M, 51% of the disclosed total, well ahead of Wound Reconstruction Solutions at 19%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.